Cara Therapeutic (CARA)

NASDAQ
14.55
-0.10(-0.68%)
After Hours
14.20
-0.35(-2.41%)
- Real-time Data
  • Volume:
    1,016,639
  • Bid/Ask:
    14.20/15.00
  • Day's Range:
    14.01 - 14.58

CARA Overview

Prev. Close
14.65
Day's Range
14.01-14.58
Revenue
128.93M
Open
14.36
52 wk Range
11.87-29.61
EPS
0.19
Volume
1,016,639
Market Cap
728.26M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,274,873
P/E Ratio
78.58
Beta
1.09
1-Year Change
-12.45%
Shares Outstanding
50,052,011
Next Earnings Date
Aug 05, 2021
What is your sentiment on Cara Therapeutic?
or
Market is currently closed. Voting is open during market hours.

Cara Therapeutic News

Cara Therapeutic Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyNeutralSell
Technical IndicatorsStrong BuyBuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyBuyStrong Sell

Cara Therapeutic Company Profile

Cara Therapeutic Company Profile

Sector
Services
Employees
80

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.

Read More
  • might as well buy a ittle, no?
    0
    • anyone know the reason of this fall ??
      0
      • Cara Therapeutics' Stock Plummets As Korsuva Flunks In Mid-Stage Atopic Dermatitis Study
        0
    • This is about to ********up. Expect a jump on Apr 8th.
      0
      • up
        0
    • According to simply wallst, the stock is heavily undervalued. Fundamentally target is $ 261.45.
      0
      • All IN!!!  till 32
        0
        • the sector of therapeutics seems to start moving in the right way. Let's see what's happen if this continue :)
          0
          • what happened??
            1
            • any thoughts on this one.
              0
              • What you think about CARA earning report in 3 days from now? Up or down after report?
                0
                • depends what they say on the conference call about filing the NDA.
                  0
              • Start accumulating $CARA as $GWPH will lift the entire cannabis sector
                2
                • I think it's going to balance out at 15 price target is at 25 now!
                  1
                  • Trail data was excellent! Don't let little bit of "profit taking" get you down!
                    0
                    • Good entry point here?
                      0
                      • Going to be good 3-6 for me
                        0
                        • it seems like a rocket....
                          0
                          • Earnings was good still looking for a nice gain today
                            0
                            • Whats happend about cara ?
                              0
                              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.